FDA opened 72 new counterfeit cases in 2010--a new record
Caseload reinforces concerns over illegal trade and distribution of pharmaceuticals
During a presentation at a meeting organized by the Pew Prescription Project (Washington, DC., March 7-8), deputy administor Dr. Ilisa Bernstein noted that 72 cases had been opened by FDA’s Office of Criminal Investigations in FY 2010 (which ended Sept. 30). That’s up nearly 11% from the year before, which was also an up year.
FDA is always careful to not impute too much meaning to this annual count; it is a measure as much of FDA activity as it is of the pace of counterfeiting business; moreover, one “investigation” can be a single pharmacist relabeling old product as much as an international ring importing pallet-loads of product (both of which occur). Still, this count is up for three years running, and has been at a level 3-5 times what was reported a decade ago. Recent incidents also include intrusions into the so-called “normal chain of distribution” defined in various state pedigree rules; this chain is supposed to be immune to external, unregulated activity. “Counterfeiting is like water pressure,” commented Allan Coukell, a Pew Prescription Project director, during the meeting. “It will find a way in.”
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.
